Human Genome (HGSI) Up On More Takeover Talk

Shares of Human Genome Sciences Inc. (Nasdaq: HGSI) are higher today as traders are again speculating about a potential takeover of the company. The stock is up nearly 2% today.

Earlier in the week, Piper Jaffray suggested in a research note that "if BLISS-76 data is positive, we see a real chance that partner GlaxoSmithKline (NYSE: GSK) acquires HGS." The firm notes GSK shares Benlysta and daraplatib for the treatment of atherosclerosis, and has rights to Syncria for diabetes. They also said HGS has a history of significant net operating loss (NOLs) that they see as a "tax-free coupon" for a potential acquirer.

Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Susquehanna Starts IBM (IBM) at Neutral
• Warburg Pincus near over $7 billion deal for specialty-pharmacy company PantheRX - WSJ